Biogen And Sangamo Announce Global Collaboration To Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular And Other Neurological Diseases; Biogen To Pay Sangamo $350M Upfront, Sangamo Eligible For Up To $2.37B In Milestones
Benzinga Newsdesk